Medicaid tries performance-based payments for gene therapies
January 25, 2026
In the spirit of value-based care, Medicaid is tying payments to the effectiveness for some gene therapies, as reported by KFF Health News. Paying only when a treatment is successful is one way of reducing risk as a payer, especially if the treatment is expensive. The details of the program are confidential, so it is unclear whether the performance-based payments are meaningful. Additionally, the program stipulates "discounts and rebates," which could reduce the appeal of the arrangement.
Nevertheless, when these treatments can cost millions of dollars, a performance-based compensation scheme makes a lot of sense. A health insurer might be willing to pay a large number if the treatment successfully avoids larger ongoing costs over the long term. In return, the participating pharmaceutical companies might be able to enjoy a more streamlined process for patients to be approved, which could lead to more sales. This arrangement could be a win-win for Medicaid and for companies that offer effective treatments.